Comments on: Webinar

By: Olivia Hughes

Olivia Hughes — Mon, 17 Aug 2026 19:07:58 +0000

Nội dung hay và thực tế. Letco là đơn vị du học Hàn Quốc giàu kinh nghiệm, đồng hành cùng học viên từ A-Z. Ghé letco.vn để được tư vấn miễn phí.

By: Anonymous

Anonymous — Fri, 10 Apr 2026 07:43:31 +0000

By: Anonymous

Anonymous — Sat, 04 Apr 2026 15:38:26 +0000

Thank you Sir for Mentioning us 🙏

By: Anonymous

Anonymous — Sat, 04 Apr 2026 15:28:50 +0000

sub-therapeutic doses can still provide clinically meaningful improvements in steatosis or fibrosis, especially for patients who cannot tolerate full-dose escalation?

By: Anonymous

Anonymous — Sat, 04 Apr 2026 15:26:20 +0000

Please comment on the risk of optic neuritis and pancreatitis with semiglutide

By: Anonymous

Anonymous — Sat, 04 Apr 2026 14:40:28 +0000

Is there any role for semaglutide in compensated and decompensated CLD secondary to MASH?

By: Anonymous

Anonymous — Sat, 04 Apr 2026 14:39:31 +0000

What’s the dose like for MASH?

By: Anonymous

Anonymous — Sat, 04 Apr 2026 14:04:11 +0000

1. Do you think lower doses of Semaglutide (since in a few of your slides there were doses of 0/1, 0.2, and 0.4mg) could still offer clinically meaningful benefits in steatosis and fibrosis, particularly in populations where full-dose escalation may not be feasible?
2. Considering Asia’s unique phenotype, including higher lean MASLD prevalence and early-onset diabetes, do you expect different responses to semaglutide compared to Western populations?
3. From your experience, what are the key practical challenges in implementing the stepwise dose escalation of semaglutide in routine clinical practice globally?

By: Anonymous

Anonymous — Sat, 04 Apr 2026 13:55:15 +0000

Effect of Semaglutide on ckd patients

By: Anonymous

Anonymous — Sat, 04 Apr 2026 13:50:27 +0000

Can we use in OSA/ weight loss